Sign in
PHVS Stock Price, Chart, Stats & News
Pharvaris N.V.
Save
2.15B
Market cap
–
Current P/E
–
Forward P/E
PHVS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -1.00% |
ROA | -48.99% |
ROE | -67.11% |
D/E | 0.00x |
Interest coverage ratio | – |
PHVS valuation
P/E | – |
P/S | – |
P/B | 4.73x |
P/CF | -11.01x |
P/FCF | -11.46x |
P/OCF | -11.01x |
PEG | -1.86x |
EV multiple | -12.04x |
About
Pharvaris N. V. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and bringing to market treatments for uncommon diseases. Its primary pipeline asset, PHA121, is a small molecule bradykinin B2-receptor antagonist currently undergoing Phase II clinical trials for hereditary angioedema (HAE).
Similar securities
Based on sector and market capitalization
Report issue